The Pharmasyntez Group of Companies’ revenue increased by 36% over 2019

The Pharmasyntez Group of Companies announced 2019 financial results: the consolidated revenue increased by 36% and reached 22.7 billion RUB (25.4 billion RUB incl. VAT)

The 2019 Earnings before Interest, Taxation, Depreciation & Amortisation (EBITDA) amounted to 5.5 billion RUB that was 26 % greater than the previous year results. EBITDA margin was 24%.

The Pharmasyntez Group of Companies ensures an uninterrupted manufacture of the pharmaceuticals, 83% of which are included in the List of Vital and Essential Drugs. The Company is engaged in further development of the product portfolio and has a number of manufacturing sites under construction.